We retrospectively investigated the relationship between PD-L1 expression and the efficacy of PD-1 inhibitors in NSCLC patients to assess the efficacy of PD-1 inhibitors in patients with an EGFR mutation and high PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.